Clariant Ag · SIX:CLN
Clariant — 9M 2020 Earnings Presentation
20 slides from Clariant's earnings presentation, Oct 29, 2020
Slide 1: Nine Months / Third Quarter 2020
Nine Months / Third Quarter 2020 29 OCTOBER 2020
Slide 2: Disclaimer
2 Nine Months / Third Quarter 2020 29 October 2020 Disclaimer This presentation contains certain statements that are the Company’s ability to continue to receive adequate neither reported financial results nor other historical products from its vendors on acceptable terms, or at all, information. an
Slide 3: First Nine Months & Third Quarter 2020 – Highlights
3 Nine Months / Third Quarter 2020 29 October 2020 First Nine Months & Third Quarter 2020 – Highlights 9M 2020 vs. 9M 2019, figures from continuing operations Q3 2020 vs. Q3 2019, figures from continuing operations SALES 2 838 - 6 % SALES 893 -7% in CHF m in LC* y-o-y in CHF m in LC* y-o-y EBITDA 41
Slide 4: Sales Development & Mix
4 Nine Months / Third Quarter 2020 29 October 2020 Sales Development & Mix All figures continuing operations − 9M 2020 sales declined by 6 % in LC* and by 9M 2020 SALES in CHF m 13 % in Swiss francs due to unfavorable currency developments of - 7 % 3 272 -8% − Weaker volume development in all Busine
Slide 5: Sales Distribution by Region
5 Nine Months / Third Quarter 2020 29 October 2020 Sales Distribution by Region Emerging markets All figures continuing operations Mature markets − In 9M 2020, sales in Asia improved in LC*, with 9M 2020 SALES CHF 2 838 m China and India reporting strong growth; sales in CHF m in Latin America also
Slide 6: Care Chemicals
6 Nine Months / Third Quarter 2020 29 October 2020 Care Chemicals 9M 2020 9M 2019 % CHF % LC* − 9M 2020 sales decreased by 5 % in LC* due to lower Sales in CHF m 1 064 1 212 - 12 % -5% Industrial Applications demand amid COVID-19, while Consumer Care sales rose, underpinned by Personal Care EBITDA i
Slide 7: Catalysis
7 Nine Months / Third Quarter 2020 29 October 2020 Catalysis 9M 2020 9M 2019 % CHF % LC* − 9M 2020 sales declined by 3 % in LC* against a strong Sales in CHF m 599 659 -9% -3% comparison base; Petrochemicals sales development outpaced Syngas and Specialty Catalysts EBITDA in CHF m 110 128 - 14 % EBI
Slide 8: Natural Resources
8 Nine Months / Third Quarter 2020 29 October 2020 Natural Resources 9M 2020 9M 2019 % CHF % LC* − 9M 2020 sales decreased by 8 % in LC* Sales in CHF m 1 175 1 401 - 16 % -8% − Sales in Oil and Mining Services (OMS) hampered by lower EBITDA in CHF m 160 219 - 27 % oil production due to weakened dema
Slide 9: Nine Months 2020 – EBITDA Development
9 Nine Months / Third Quarter 2020 29 October 2020 Nine Months 2020 – EBITDA Development All figures continuing operations 9M EBITDA / margin − 9M 2020 EBITDA declined to CHF 419 m in CHF m / in % of sales compared to an EBITDA of CHF 484 m in 14.8 % 14.8 % 500 14.1 % 9M 2019 (excluding the one-off
Slide 10: Third Quarter 2020 – EBITDA Development
10 Nine Months / Third Quarter 2020 29 October 2020 Third Quarter 2020 – EBITDA Development All figures continuing operations Q3 EBITDA / margin − Q3 2020 EBITDA declined to CHF 127 m in CHF m / in % of sales from CHF 151 m in Q3 2019 − The corresponding EBITDA margin declined 14.5 % 14.2 % 180 160
Slide 11: Outlook
a CLARIANT Outlook what is precious to you?
Slide 12: Continued, but slightly less negative COVID-19 impact in Q4
12 Nine Months / Third Quarter 2020 29 October 2020 Continued, but slightly less negative COVID-19 impact in Q4 while performance measures and the transformation program are progressed − Sales declined by 6 % in LC* in 9M 2020 impacted by the weaker demand environment as a result of the COVID-19 pan
Slide 13: Back-up Slides
a CLARIANT Back-up Slides what is precious to you?
Slide 14: A More Focused, High Value Specialty Portfolio
14 Nine Months / Third Quarter 2020 29 October 2020 A More Focused, High Value Specialty Portfolio Continuing Operations: Sales growth Sales growth Sales growth expectation p.a. 5-7% expectation p.a. 6-9% expectation p.a. 5-7% EBITDA EBITDA EBITDA 19 - 21 % 26 - 30 % 18 - 20 % margin ambition margin
Slide 15: Discontinued Operations (Masterbatches and Pigments)
15 Nine Months / Third Quarter 2020 29 October 2020 Discontinued Operations (Masterbatches and Pigments) 9M 2020 9M 2019 % CHF % LC* − In 9M 2020, sales decreased by 25 % in LC* and 31 % in Sales in CHF m 1 130 1 637 - 31 % - 25 % Swiss francs EBITDA in CHF m 829 115 n.m. − On a like-for-like basis
Slide 16: Nine Months 2020 – Sales and EBITDA by Business Area
16 Nine Months / Third Quarter 2020 29 October 2020 Nine Months 2020 – Sales and EBITDA by Business Area Sales to 3rd parties EBITDA Nine Months 2020 in CHF m 2020 2019 % LC* 2020*** 2019 % CHF Care Chemicals 1 064 1 212 -5% 192 212 -9% margin 18.0 % 17.5 % Catalysis 599 659 -3% 110 128 - 14 % margi
Slide 17: Full Year 2019 – Sales and EBITDA by Business Area
17 Nine Months / Third Quarter 2020 29 October 2020 Full Year 2019 – Sales and EBITDA by Business Area Sales to 3rd parties EBITDA Full Year 2019 in CHF m 2019 2018 % LC* 2019 2018 % CHF Care Chemicals 1 600 1 665 -1% 282 314 - 10 % margin 17.6 % 18.9 % Catalysis 925 861 +9% 212 185 + 15 % margin 22
Slide 18: Update on COVID-19 mitigation measures
18 Nine Months / Third Quarter 2020 29 October 2020 Update on COVID-19 mitigation measures • Safety of our employees – resurgence of COVID-19 triggered Clariant’s GEM organization to return to stricter rules on social distancing, home office arrangements and travel bans similar to the Q2 2020 lockdo
Slide 19: Calendar of Upcoming Corporate Events
19 Nine Months / Third Quarter 2020 29 October 2020 Calendar of Upcoming Corporate Events 11 February 2021 Full Year 2020 Reporting 07 April 2021 Annual General Meeting
Slide 20: IR Contacts
20 Nine Months / Third Quarter 2020 29 October 2020 IR Contacts Maria Ivek Phone: +41 61 469 63 73 Senior Investor Relations Officer Email: investor-relations@clariant.com Alexander Kamb Investor Relations Officer